The Office of Translation to Practice (OTP) is housed in the Center for Clinical and Translational Sciences at Mayo Clinic. Established in 2015, the office was tasked with developing and managing novel tools, mechanisms, and processes to facilitate and accelerate the translation of products, such as drugs, biological agents, and medical devices, into practice. Since its inception, the OTP is credited with creating valuable services through several strategic alliances and active scientific and project management involvement. The OTP continues to move forward to assist Mayo Clinic physicians and scientists to interact effectively with internal and external collaborators to advance translational projects that will benefit patients. Best practices, innovations, and nascent successes of the OTP are presented and discussed herein.
I
n January 1925, Dr Charlie Mayo gave the welcome address at the ninth annual meeting of the American Association for Thoracic Surgery and noted, "Today, it is impossible for any one man to know more than a little of comparatively few things." 1 This was not an admission of defeat, but instead a declaration that Mayo Clinic had come to embrace a team-based approach to medicine that remains today as one of the pillars of the Mayo Clinic Model of Care. 2 This Model of Care likewise embraces the mantra of Dr Will Mayo Sr that "No man is big enough to be independent of others." 3 Over time, this position has become more widely adopted, leading to the specialization of medical and scientific professionals.
Specialization allows these professionals to become a member of a medical or scientific team and thus, the creation of multiple avenues for postgraduate medical education and post-PhD doctoral training. Two statistics are illustrative. A recent estimate from the Association of American Medical Colleges is that 77.5% of medical school graduates complete at least 1 residency training program within 4 years of graduating. 4 The number of postdoctorals in health-related fields increased by nearly 200% from 1979 to 2012. 5 Alternative specialization avenues, focused on translating inventions to medical products, also now exist. Included among these is the more recent practice of MD and PhD scientists receiving formal training in legal, business, intellectual property, or sales and marketing. These individuals become bridge-building specialists, able to translate and bridge effectively science/medicine and business. One indicator of this is the general trend seen with joint MD/MBA programs, the number of which has, relatively recently, increased more than 10-fold in 20 years. 6 
NCATS AND CCATS
The team science paradigm posits that teams comprising highly specialized, complementary team members are optimal for translating products into practice. In recognition of the need for added infrastructure to support/coordinate formation of such teams, a national center for advancing translational sciences was established as part of the National Institutes of Health in 2012, 7 
now
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From 9 The CCaTS is a leader in the field of team science and has pioneered and supported numerous initiatives to achieve the broad goals of the NCATS, including creation of the Clinical Research and Trials Unit, 10 CCaTS educational resources, 11 CCaTS consultative resources, 12 the Informatics for Integrating Biology and the Bedside informatics framework, 13 and the focus of this manuscript, the Office of Translation to Practice (OTP). 14 
OFFICE OF TRANSLATION TO PRACTICE
The recognition of the need for an OTP and the envisioning. establishment, and success of the OTP reflect the following 4 salient considerations: first, the enduring legacy and commitment to teamwork at Mayo Clinic; second, individual insights and initiatives integrated into and underpinning a unified team-based approach; third, the responsivity of institutional leadership in addressing unmet needs in clinical research and clinical translation; and, fourth, a research structure and milieu that facilitate the collaboration of centers and groups with dovetailing interests. In May of 2011 an internal services gap was identified by 1 of us (A.D.B.) in the field of drug development as his laboratory sought to develop novel therapies for human immunodeficiency virus and other chronic infectious diseases based on basic scientific discoveries in his laboratory. 15, 16 The delineation of this need to Mayo Clinic Research Leadership for a clinical translational conduit led to an invitation to Dr Badley to form and lead a Drug Discovery Steering Committee (see Table 1 for full timeline). The committee quickly identified accessing or developing high-throughput screening capabilities as a critical first challenge. The solution to this first problem was a formal strategic alliance with the Sanford Burnham Prebys (SBP) Medical Discovery Institute. Pilot drug screening projects, submitted in response to an internal request for applications, are selected by joint institutional review on the basis of druggability and quality of science (described more fully later herein).
In the wake of early successes of the SBP alliance, Drs Badley and Khosla, representing CCaTS Leadership, formed the OTP in the CCaTS, with Dr Badley as founding director. The office supports the development of various products, including, but not limited to, drugs, therapeutics, medical devices, and diagnostics. The mission of the OTP is "to facilitate and accelerate the translation of novel products into clinical practice by enabling bidirectional interactions between strategic academic and industry collaborators and Mayo Clinic researchers." 17,p1 As the mission statement implies, strategic alliances both within Mayo Clinic and with external collaborators have been used extensively by the OTP to address the gaps that the OTP identifies. From the perspective of team science, a commonality or common effect of the OTP is that additional team members are made available to the scientific/clinical The OTP aligns with and supports the Mayo Clinic Model of Research: discovery, translation, and application ( Figure 1 ). The discovery step is realized by physicians and scientists at Mayo Clinic working together (team science) to conduct discovery science. Discovery science at Mayo Clinic is focused exclusively on the unmet needs of patients in alignment with Mayo Clinic's foundational and primary value that "the needs of the patient come first" 19 and is a hallmark of Mayo Clinic. 20 The OTP exists to facilitate and accelerate the handoff between discovery and translation. To realize this mandate, the OTP has developed innovative tools, mechanisms, and processes at Mayo Clinic. These accelerate the cycle of innovation to affect and provide avenues and access to industry that augment the final step in the Mayo Clinic Model of Research, application.
The efforts of the OTP have shown early success and have helped numerous scientists and physicians at Mayo Clinic to prioritize product development on par with the more traditional goals of obtaining extramural support and scientific publication. We hope and anticipate that this trend will become even more widespread in the future. Herein we describe these efforts and successes.
PORTFOLIO OF VETTED STRATEGIC ALLIANCES
The initial strategic development of OTP resources has been in the drug discovery and cellular therapy space. Innovation in this space not only aligns well with the strong discovery science efforts at Mayo Clinic but also aligns with current needs in the pharmaceutical industry and, most importantly, the needs of the patient. Recent reports have highlighted the increasing costs incurred in drug development. 21 Cost increases have resulted in, among other trends, longer time to market for drugs and increased reliance by pharma on other institutions to perform discovery efforts. 21 As has been noted, the first task of the OTP was to assess the most effective means to bring high-throughput screening and other drug discovery capabilities to Mayo Clinic and Mayo Clinic research groups. The OTP was thus tasked with the "most critical question" 22 for any company or group: whether to build, buy, or partner to address the need. Partnering was determined to be the most advantageous approach, recognizing that this would be a long-term need. Building this capability internally was deemed disadvantageous due to the high costs to build, maintain, and continuously upgrade a drug screening facility. Likewise, in view of the long-term nature of the need, buying drug screening services from contract research organizations was deemed too costly. Partnering offered the ability to (1) quickly begin drug screening efforts, (2) access much more extensive and varied drug libraries than could have been built in-house, (3) access not only equipment and services but also the expertise of the partnering institution, and (4) engage in a long-term strategic alliance as a long-term solution to the needs assessment. After a comprehensive search, the OTP selected the SBP Medical Discovery Institute as its partner in this effort. 23 Notably, the academic philosophy of SBP, a not-for-profit research organization, was deemed to be particularly advantageous from a strategic fit perspective. The operational and chemistry/ culture fits between Mayo and SBP were also found to be complementary, as enabled through the vehicle of the OTP, in the "fit analysis." 22 Access to the drug screening capabilities at SBP is organized internally as a competitive award mechanism and has fielded, to date, more than 70 proposals. Structuring access as an award mechanism is deliberate. This allows the quality of the science within proposals to be the main determinant for projects brought into the collaboration. Seed money is contributed directly to the projects, bringing together the Mayo scientific/ clinical team, SBP drug screening/chemistry experts, and OTP translational managers to create and then validate a custom pilot drug screen on a small molecule collection (5-50,000 compounds) toward a meaningful target. The mechanism is also self-sustaining because all projects are designed such that drug screening activities under the collaboration result in a preliminary data package for subsequent joint applications for competitive funding (National Institutes of Health, foundational funding, pharma open innovation programs, etc). Furthermore, this mechanism appropriately shares risk and reward between the 2 institutions; foreground intellectual property is shared between the 2 institutions as part of the formal agreement and was prenegotiated in line with best practices of strategic alliance management. 22 A pipeline of projects has now been established. Twenty-two projects have been accepted into the program, impacting diverse indications, of which 17 have completed a design of an initial drug screen and 5 are in process. Seven projects have progressed beyond this point, with 5 having completed high-throughput screens and 2 in process ( Figure 2 ). Thus far, 4 validated drug hits have been identified and continue to progress. To date, coegrant application after screening has resulted in an almost 6-fold return on investment as competitive funds have been successfully applied for and awarded from multiple sources (Figure 2) . The alliance has provided access to medicinal chemistry resources, expanded grant funding sources, and increased translational research in drug discovery and development at Mayo Clinic (and SBP), thus changing the culture of drug development at Mayo Clinic.
Of note, this alliance has now engaged in further innovation in terms of alliance structure. The initial need of drug screening capabilities has led to a new need for hit-to-lead optimization of drug candidates. Mayo Clinic and SBP continue to partner together to address this related challenge and currently have 3 projects at this stage of development, 1 of which is currently under review by potential big pharma partners (Figure 2 ). Other gaps in the drug development pathway have also been identified by the OTP, resulting now in a stable of vetted strategic contract research organizations, consultants, key opinion leaders, and collaborators in this space. Currently, efforts are underway to develop a similar network of partners to facilitate the development of products other than small molecule drugs.
NOVEL MECHANISMS THAT FACILITATE AND ACCELERATE TRANSLATION TO PRACTICE
The drug development work of the OTP has led to numerous discussions with professionals in the drug development and commercialization industry. Those discussions and interactions led the OTP to identify a notable gap not internal to Mayo but external in this community of professionals: the need for direction and expert advice from Mayo Clinic clinicians in (1) assessing or vetting potential drug assets and (2) designing and implementing the best clinical trials.
Poor pharmacokinetics and pharmacodynamics of a drug, inadequate trial design, misguided selection of the patient population, and inappropriate trial end point selection have been suggested as major reasons why many late-phase clinical trials fail. 24 The cross-functional teams of physician scientists with various specialties and from various departments that are part of the existing Mayo culture are well suited to address such issues when designing clinical trials. Not only do these physicianscientists bring their unique clinical and investigative expertise, but as so many clinical trials are conducted at Mayo Clinic, they are intimately aware of the cutting edge of drug development. What was initially not evident was the uniqueness of the cross-functionality of these teams. Although advisory boards are ubiquitous in pharma, the ability to source all members of such a board from a single institution combined with the ability to easily pull in experts from fields other than that of the initially envisioned indication (eg, to bring in a nephrologist to comment on an oncology asset) is something that is novel and innovative. This concept has been formalized by the OTP as Translation Boards. One visible value-add of these Translation Boards is the formation of new, Mayofounded startup companies. 25 One such company is Qrativ, which was formed in 2017 and brought together Mayo Clinic and nference ( Figure 3) . nference is an analytics company that has developed novel techniques to synthesize and sound all existing biomedical literature. Their analytics platform, nferX, "uses state-of-the-art Neural Networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific, and regulatory body of literature." 26 This specialization meshes well with the concept of Translation Boards. Mayo Clinic Translation Boards work with the nference team through Qrativ to identify existing drugs at a late preclinical or early clinical phase with latent potential. The OTP-led Translation Boards further advise, regarding assets that are acquired, to design and conduct critical clinical trials that further the developmental stage of the drugs.
Qrativ is also leveraging Mayo Clinic's proprietary data to create a new knowledge synthesis platform, Darwin.ai. This platform will "combine nference's knowledge synthesis platform with the clinical expertise of Mayo Clinic physicians and scientists." 26 Darwin.ai may also prove to be an additional tool to augment the translational research efforts of scientific teams at Mayo independent of Qrativ's primary focus to develop new pharmaceuticals.
The use structure of Translation Boards within Qrativ is just one of the many possible implementations of Translation Boards. 27 Much like efforts with SBP, the OTP plans to build on the successes of Qrativ to engage additional external partners in disseminating this new tool over a broad variety of industries.
PROJECT-SPECIFIC MANAGEMENT TEAMS
Additional processes have necessarily accompanied the efforts of the OTP. These processes are exemplified by the concept of OTP-led, project-specific management teams ( Figure 4) . As products progress on the developmental pathway, various specialists may be required to advise and participate in product development. The OTP provides a nexus for organization and management of projectspecific management teams that respond agilely to fluctuating and evolving team needs. Additional team members brought on by the OTP augment the core scientific teams that the OTP services.
To facilitate the population of these teams, the OTP team leaders partner with the various internal offices and support services at Mayo Clinic and also have curated a list of external consultants. External consultants include, among others, experts in regulatory affairs, reimbursement strategy, and business intelligence ( Table 2) .
Project-specific management teams have been used extensively in an additional success of the OTP, co-administering the Translational Product Development Fund (TPDF) with the University of Minnesota (UMN) Office of Discovery and Translation. The TPDF is a competitive funding mechanism established by the CCaTS and the UMN Clinical and Translational Science Institute in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics.
28
Similar to the main Minnesota Partnership, the TPDF leverages the generous support of the State of Minnesota to position Minnesota as a world leader in biotechnology, stimulate the regional economy and industry, and realize breakthrough therapies. 29 Ultimately, the intent of the program is to "impact the lives of Minnesotans by translating research discoveries into new therapies and treatment approaches for patients."
28 It does this through milestone-based, tiered funding of translational projects at the UMN and Mayo Clinic. For each project on which the lead principal investigator or coeprincipal investigator is from Mayo Clinic, the OTP provides oversight and assembles a project-specific management team. The OTP advises and coordinates when additional team members are needed and assists as appropriate to help teams realize their milestone goals. Since June 2015, more than 150 letters of intent have been received for the TPDF, resulting in 15 tier 1 ($50,000 for 1 year) and 2 subsequent tier 2 awards ($400,000 over 2 years) committed. Awarded projects have been distributed across different types of products, including drugs and biological agents, medical devices, biomarkers and diagnostics, and software. Many of these TPDF projects continue to progress toward commercialization, and resources for additional rounds of funding of the TPDF have been secured. Recently, based on its successes, the TPDF received a 1-time $2.5 million bolus of additional funding, above its current support from the Minnesota Legislature, through a bill championed by Rep. Matt Dean, chairman of the Minnesota State House Health and Human Services Finance Committee. 30 A standout example of the innovation supported by the TPDF is seen in the work of Mayo Clinic's Dr Barry Borlaug to develop new tools and procedures to treat heart failure with preserved ejection fraction (HFpEF), a subtype of heart failure that is currently untreatable. Using TPDF funding, Dr Borlaug has prototyped and tested novel, minimally invasive surgical tools for a completely new surgical intervention for HFpEF: percutaneous pericardial resection. This work has been partly captured in a recent publication that was recognized as a "best paper" by the Heart Failure Society of America at their yearly conference in September 2017. 31 Through the TPDF award, the new surgical tools have been prototyped over multiple iterations, acute and further chronic testing in an animal model of HFpEF has been performed, and proof of principle mechanistic studies in humans have been performed. These activities have significantly derisked this new product that is intended to assist a significant population that currently has no viable treatment options. 31 The TPDF mechanism has had such great success that in 2018 Mayo Clinic decided to develop a similar program on an institutional level. The Advance the Practice Research Award provides critical support in the form of interaction with the OTP product-specific project management teams as well as a $50,000 award. Projects are limited to either development of an earlystage product or transformative practice initiatives or pilots. Although just in its infancy, it is expected that this critical infusion of focused support at an early stage of product development will have great impact.
MAYO CLINIC VENTURESdA CRITICAL INTERNAL PARTNER
A final, important "key to success" of the OTP is seamless interaction with MCV, the 
CONCLUSION
The OTP's effort to introduce projectspecific management teams, Translation Boards and vetted strategic collaborators has changed the culture at Mayo Clinic. Table 2 summarizes these resources using examples (that are not meant to be limiting).
As the OTP enters its third year of existence, more basic and clinical scientists are contacting the group and engaging in efforts to translate their scientific discoveries into patient-focused products. We anticipate that the early successes highlighted herein will continue to progress and be augmented by new success stories, startups, and successful commercialization of medical products that will benefit patients at Mayo Clinic and abroad.
We are confident that the OTP, assisted by integral partners, both internal and external (eg, SBP, Qrativ, and MCV), will continue to lead the development of Mayo Clinic products for unmet medical needs. These efforts will not only realize success but are intended to accelerate the cycle of innovation to impact. We aspire to do this for the patients, whose needs always come first, and so that Mayo Clinic's legacy and Model of Care will be enabled to continue forward undiminished to the next generation and beyond.
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